Designing circulating tumor DNA-based interventional clinical trials in oncology

Daniel V Araujo1, Scott V Bratman2, Lillian L Siu3

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Genome Medicine
|April 21, 2019
PubMed

Insights

Circulating tumor DNA (ctDNA) offers a dynamic way to monitor cancer progression and treatment response. This powerful tool is being integrated into clinical trials for improved patient management and therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Research

Background:

  • Circulating tumor DNA (ctDNA) provides a non-invasive method for real-time cancer monitoring.
  • ctDNA analysis has shown promise in various oncological applications.
  • Integrating ctDNA into clinical trials is a critical next step for its widespread adoption.

Purpose of the Study:

  • To discuss the incorporation of ctDNA analysis into clinical trial designs.
  • To highlight the potential applications of ctDNA in oncology.
  • To explore how ctDNA can enhance patient stratification and treatment monitoring.

Main Methods:

  • Review of current literature and clinical trial methodologies.
  • Discussion of ctDNA's role in detecting minimal residual disease and predicting relapse.
  • Analysis of ctDNA's utility in patient selection for targeted therapies.

Main Results:

  • ctDNA can track cancer dynamics beyond single time points.
  • Potential for ctDNA in early detection of relapse and guiding treatment decisions.
  • ctDNA aids in understanding mechanisms of treatment response and resistance.

Conclusions:

  • ctDNA is a valuable biomarker for cancer management.
  • Incorporating ctDNA into clinical trials will accelerate its therapeutic use.
  • Further research and standardization are needed for optimal ctDNA implementation.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Community Based Intervention01:30

Community Based Intervention

Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
288
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
DNA Base Pairing02:27

DNA Base Pairing

Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
33.1K
DNA Base Pairing02:27

DNA Base Pairing

32.1K